SB1076 amends Arizona’s newborn screening statute to require the Department of Health Services to add Duchenne muscular dystrophy (DMD) to the state’s newborn screening panel, in addition to the disorders already required under the federal Recommended Uniform Screening Panel. The bill keeps the existing framework for newborn and infant screening, including reporting requirements, follow-up services, a central database, an advisory committee, and the department’s authority to set a program fee.
The bill also sets the timing for implementation. The amended section becomes effective on the earlier of October 1, 2027, or two years after DMD is added to the federal recommended screening panel. The department must notify the Arizona Legislative Council within ten days after DMD is added to the federal panel. The bill preserves the department’s authority to contract for testing and to designate laboratories, while requiring privacy and sample-destruction rules to be followed by any designated lab.
Impact
SB1076 would expand Arizona’s mandatory newborn screening program by adding Duchenne muscular dystrophy to the list of conditions screened at birth. This would affect the Department of Health Services, the state laboratory and any authorized testing facilities, health insurers subject to Title 20, and AHCCCS contractors, because the bill requires fee-related hospital rate updates if the newborn screening program fee changes. It also reinforces existing reporting, confidentiality, and follow-up obligations tied to newborn and infant screening under A.R.S. § 36-694.
Sentiment
The bill appears to have broad support. It passed the Senate Health and Human Services Committee unanimously, the Senate Appropriations Committee unanimously, and the House Health & Human Services Committee and House Appropriations Committee unanimously as well. It also passed the Senate floor by a strong margin, though not unanimously, indicating generally favorable sentiment with limited opposition.
Contention
The main policy issue is whether Arizona should add Duchenne muscular dystrophy to the newborn screening panel before it is federally required, and how quickly the state should implement the change. Any concerns are likely centered on program costs, laboratory capacity, and the downstream impact on insurers and AHCCCS rates because the bill allows the department to set a fee and requires rate adjustments when that fee changes. The recorded votes show little committee-level contention, suggesting any disagreement was limited and did not prevent advancement.